US lawmakers urge administration to take action against Wuxi

2024-02-14

抗体药物偶联物

US lawmakers urge administration to take action against Wuxi

Preview

来源: Pharmaceutical Technology

WuXi has signed a number of partnerships that have strengthened its global reach. Credits: 010110010101101/Shutterstock.com

In a letter to the US Departments of Treasury, Defense, and Commerce, four lawmakers have expressed their concerns regarding biotech WuXi AppTec and its subsidiary WuXi Biologics’ supposed ties to the Chinese military.

The 12 February letter from Chairman Mike Gallagher (R-WI), Senator Bill Hagerty (R-TN), Ranking Member Raja Krishnamoorthi (D-IL), and Senator Gary Peters (D-MI) asked that the administration add Wuxi to US government control lists given the biotech’s alleged ties to the Chinese Communist Party (CCP) and involvement in the CCP genocide of Uyghurs in Xinjiang, Reuters first reported.

In addition, the letter alleges that the biotech is “closely affiliated” with the People’s Liberation Army (PLA), claiming that the biotech’s chairman and CEO Dr. Li has “personally commended CCP branch work in the company and has called on Party branches and members to play an active role in the company.”

Lawmakers also claim that CEO Chen Zhisheng of WuXi Biologics, which is a global contract research development and manufacturing organization giant, has attributed the organisation’s success to local CCP support.

Reuters reported that Wuxi has previously said it does not pose a national security risk to any country.

See Also:China-US tensions are spilling into the biotech sector

Preview

来源: Pharmaceutical Technology

BMS steps closer to expanding Augtyro’s use for treating NTRK+ solid tumours NTRK+ solid tumours

Preview

来源: Pharmaceutical Technology

Over the past year, WuXi has made strides and signed several partnerships that expand its global footprint.

In May 2023, WuXi Biologics agreed to provide Jena, Germany-based InflaRx with cGMP manufacturing services to advance Gohibic (vilobelimab), an investigational first-in-class monoclonal anti-human complement factor C5a antibody complement factor C5a antibody, as a treatment for a specific group of critically ill Covid-19 patients.

The CDMO also signed an agreement with IMIDomics in October 2023 to progress the development and manufacturing of the San Rafael, California-based company’s humanised antibody IMB1001 for immune-mediated inflammatory diseases (IMIDs).

Most recently in November 2023, UK-based Myricx Bio collaborated with WuXi Biologics on a deal that will see Myricx use WuXi’s antibody to develop an antibody-drug conjugate using its NMTi payload platform.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构